Hubungan Dosis Dan Durasi Pemberian Atorvastatin Terhadap Outcome Terapi Pasien Penyakit Jantung Koroner
DOI:
https://doi.org/10.25273/pharmed.v4i1.8475Abstract
Atorvastatin merupakan obat golongan statin yang lebih efektif menurunkan LDL-C dan resiko penyakit kardiovaskuler. Pemilihan dosis terapi atorvastatin yang tepat dapat menurunkan pasien untuk mencapai target LDL <70 mg/dL sebagai parameter keberhasilan terapi. Penggunaan atorvastatin mempunyai efek maksimum dalam waktu 2 minggu dan mencapai efek stady state dalam waktu 5 hari. Tujuan dari penelitian ini adalah untuk mengetahui dosis dan durasi pemberian atorvastatin dapat mencapai outcome tarapi pasien penyakit jantung koroner di Rumah Sakit Panti Waluyo Surakarta. Penelitian ini menggunakan metode cross sectional dengan penelusuran terhadap rekam medis pasien secara retrospektif dan dianalisis menggunakan Chi-square. Subyek penelitian ini yaitu pasien jantung koroner yang mendapatkan terapi atorvastatin minimal 1 bulan yang kemudian dilihat kadar LDL <70 mg/dL. Dari total 85 pasien diperoleh hasil analisis hubungan dosis atorvastatin (p=1,000) dan durasi atorvastatin (p=0,519) terhadap tercapainya target LDL <70 mg/dL.
Downloads
References
Hulten, E., Jackson, J. L., Douglas, K., George, S., & Villines, T. C. (2006). The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. Archives of Internal Medicine, 166(17), 1814. https://doi.org/10.1001/archinte.166.17.1814
Kabo, P. (2008). Penyakit jantung koroner. Gramedia Pustaka utama.
Lewis, S.L., Dirksen, S.R., Heitkemper, M.M., Bucher, L., dan C. (2010). No TitleMedical-Surgical Nursing: Assessment and Management of Clinical Problems, 8th Edition (8th editio). Elsevier Mosby.
Mahamuni, S. P., Khose, R. D., Menaa, F., & Badole, S. L. (2012). Therapeutic approaches to drug targets in hyperlipidemia. BioMedicine, 2(4), 137–146. https://doi.org/10.1016/j.biomed.2012.08.002
Marrett, E., Zhao, C., Zhang, N. J., Zhang, Q., Ramey, D. R., Tomassini, J. E., Tershakovec, A. M., & Neff, D. R. (2014). Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. Vascular Health and Risk Management, 10, 237–246. https://doi.org/10.2147/VHRM.S54886
Page, R.L dan Napi, J. . (2013). Acut Coronary syndrome. In Koda-Kimble and Young’s applied Therapeutics The Clinical Use of Drug (p. 408). Phialadelphia.
Price, S.. dan Wilson, L. (2006). Patofisiologi Konsep Klinik Proses Penyakit (4th ed.). Penerbit Buku Kedokteran.
Schwartz, G. G. (2001). Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes, The MIRACL Study: A Randomized Controlled Trial. JAMA, 285(13), 1711. https://doi.org/10.1001/jama.285.13.1711
Sorrentino, M. (2012). An update on statin alternatives and adjuncts. Clinical Lipidology, 7, 721–730. https://doi.org/10.2217/clp.12.66
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Merz, C. N. B., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-jones, D. M., Mcbride, P., Schwartz, J. S., Shero, S. T., Smith, S. C., Watson, K., Wilson, P. W. F., Anderson, J. L., Halperin, J. L., Albert, N. M., … Shen, W. (2014). ACC / AHA Prevention Guideline 2013 ACC / AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidel. 1–45. https://doi.org/10.1161/01.cir.0000437738.63853.7a
Wiklund, O., Pirazzi, C., & Romeo, S. (2013). Monitoring of Lipids , Enzymes , and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. https://doi.org/10.1007/s11886-013-0397-8
Zheng, W., Zhang, Y. J., Bu, X. T., Guo, X. Z., Hu, D. Y., Li, Z. Q., & Sun, J. (2017). LDL-cholesterol goal attainment under persistent Lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (United States), 96(46). https://doi.org/10.1097/MD.0000000000008555
Downloads
Additional Files
Published
Issue
Section
License
With the receipt of the article by Pharmed Editorial Board and the decision to be published, the copyright regarding the article will be transferred to Pharmed Journal.
Pharmed has the right to multiply and distribute the article and every author is not allowed to publish the same article that was published in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
